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racking Cell Fate
ith Noninvasive Imaging*
ary S. Feigenbaum, BA, Louis Lemberg, MD,
oshua M. Hare, MD
iami, Florida
ell-based cardiac therapy is emerging as a potential strat-
gy (1) to address substantial unmet clinical needs in
ardiovascular medicine (2). Unlike all other therapies
mployed in the treatment of acute and chronic ischemic
eart disease, cell-based therapies are conceived to replace
ost myocardium (3). There is evidence comprising both
asic science (4) and early clinical trials (5) that, together,
upports the safety and efficacy of cell therapy for heart
isease. The work to date has led to a set of key questions
ertaining to dosage, delivery, and timing of cell therapy
hat must be answered to advance the field. In this context,
ethodologies to track the fate of injected cells and their
herapeutic impact are paramount.
See page 1619
In this issue of the Journal, Terrovitis et al. (6) address
racking cell fate by the use of positron emission tomogra-
hy (PET) to detect cardiosphere-derived stem cells
CDCs) (7) labeled with [18F]-fluoro-deoxy-glucose
18FDG), an agent in clinical use (8). The goal of the
uthors was to track the fate of cells employing different
elivery strategies that can be implemented in clinical
ractice. In a demonstration of their approach, the authors
cutely evaluated different injection efficiencies in a rodent
nfarct model and confirmed their results with quantitative
olymerase chain reaction (PCR). Additionally, the authors
ttempted to determine the effects of acute retention on
ong-term engraftment and function with quantitative
CR, immunohistochemistry, and echocardiography.
The rats, after undergoing infarction by left anterior
escending coronary artery permanent ligation, received
irect intramyocardial injection of CDCs into 2 sites within
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Medicine, Cardiovascular Division and the Interdiscipli-
ary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami,m
lorida. This work is supported by RO1s HL084275, AG025017, HL065455, and
L094849, and Specialized Centers for Cell-based Therapy Grant U54 HL081028.he infarcted area. Cardiac arrest was found to enhance
mmediate cell retention to the greatest extent, whereas
denosine-induced bradycardia, fibrin glue, and a combina-
ion of the 2 all increased cell retention significantly acutely
nd in the long term.
Technological advances have been rooted in delivering as
any cells as possible to the infarcted myocardium; yet, the
uantity of cells required to achieve the highest degree of
epair is unknown (9). For instance, a particularly clinically
elevant observation by Terrovitis et al. (6) is the effect of
ardiac arrest on cellular retention. This observation could
e of clinical relevance for cell delivery at the time of cardiac
urgery, where time on cardiac bypass should be limited to
minimum. However, should cell retention prove to be
rucial to long-term response, a 5-fold increase might
arrant limiting cardiac blood flow during injection. This is
lso relevant for the choice of cardiovascular support during
urgery—on or off cardiopulmonary bypass (10).
The PET-FDG provided an accurate estimate of cell
elivery—but is this all that we need to know? Factors other
han delivery quantity determine functional outcome. Cells
hat engraft might have the capacity to proliferate during
ifferentiation; thus the outcome of cell therapy might
epend on more than the quantity of cells retained. This
oncept is supported by the finding of Hamamoto et al.
11), in which a flat dose response to a wide range of
oncentrations of mesenchymal precursor cells was revealed.
ndeed, a recent comprehensive meta-analysis also supports
he idea that both higher and lower cell doses can provide
eaningful clinical benefits (12).
With these considerations in mind, imaging technology is
rucial, because current tracking and imaging modalities are
ble to not only track and quantify cell fate but also
etermine their functional effects on the host environment.
n this regard, Terrovitis et al. (6) employed computed
omography (CT) in conjunction with PET to anatomically
egister and track the cells but did not extrapolate any
unctional data from these images. As previous work has
hown, using multiple imaging types can enhance the
tructural and functional assessment of the post-stem cell
ransplant heart (13), and importantly CT is emerging as a
odality capable of examining both regional and global
ardiac function, delineating infarct size, and precisely
escribing the anatomic ultrastructure associated with a
egenerative response.
The choice of PET to track the cells in vivo provides
larity and contrast in differentiating tagged cells from the
ative heart (14) and allows for precise quantification.
lthough PET is extremely robust at this, it lacks the spatial
nd temporal resolution afforded by other imaging types,
ncluding the ability to functionally phenotype the heart.
dditionally, current PET tagging compounds have short
alf-lives limiting their use for longitudinal investigations.
hese deficiencies might be overcome in other imaging
odalities, such as CT and magnetic resonance imaging
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haracterization (15).
Magnetic resonance imaging, for instance, provides con-
rast between materials and can measure function intri-
ately, including morphology, regional contractility, and
yocardial perfusion. Cell labeling has been achieved with
uper paramagnetic iron oxide particles (Molday ION
hodamine B, Biopal Inc., Worcester, Massachusetts),
hich are readily taken up by cells. Precise quantification is
ore complex with MRI (16), but it has the unique ability
o track cell spread and movement, and repeated scanning
oses minimal risk. An MRI can also localize specific
ocations in 3 dimensions (17), significant due to the
ocalized nature of cell-based therapies.
All imaging modalities, however, have suffered from lack
f robust labeling techniques. Many labeling techniques,
equiring large amounts of resources and materials to
fficiently label clinically relevant quantities of cells, only
unction in the short-term (18); and later proliferation,
rucial to cell therapy, has been difficult to track (19,20).
ecent work aimed at remedying these problems has used
ransgenic molecular labeling techniques. For example, var-
ous detectable proteins such as red fluorescent protein,
refly luciferase, and herpes simplex virus thymidine kinase,
an be employed as a multimodality detectable set of genes
hat can be transduced into a cell’s genome. Organization of
he genes behind specific promoters for proliferation and
ifferentiation allow for the in vivo cell fate to be deter-
ined (21,22). Although these approaches are promising at
he experimental level for distinguishing between cell en-
raftment and differentiation, their clinical application poses
dditional regulatory challenges.
Imaging technology has the potential to facilitate the
evelopment of the cell therapy field by offering cell-
racking coupled to functional imaging of the organ in
uestion. As the study by Terrovitis et al. (6) reveals,
xisting clinical approaches and reagents can be applied to
rack cell fate and can aid in clinical trials. It is important to
gain emphasize that the quantity of cells delivered might
ot necessarily equate with therapeutic outcome, but it is
he application of multimodality imaging that is a likely
venue to provide the answers. Biological considerations
ndicate that outcomes result from the interplay of cell
elivery and the long-term survival, mitosis, and rates of
ifferentiation of the delivered cells. Ultimately, the promise
f noninvasive imaging is that each of the features can be
easured over time. The ultimate promise of imaging is
hat cell properties can be linked spatially and temporally to
he phenotype of the recovering heart.
eprint requests and correspondence: Dr. Joshua M. Hare,
nterdisciplinary Stem Cell Institute, 1501 NW 10th Avenue,
RB 824, Miami, Florida 33136. E-mail: JHare@med.miami.edu.
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